Neuroconnectivity and valproic acid: The myelin hypothesis

Neuroscience and Biobehavioral Reviews

Volumn 36, Issue 8, 2012, Pages 1848-1856

  Rosenzweig, Ivana ^a   Vukadinovic, Zoran ^b   Turner, Anthony J ^c   Catani, Marco ^d  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Autism; Cognition; Diffusion imaging; Epilepsy; HDAC inhibitors; Myelination; Neuroplasticity; Valproic acid

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MYELIN; VALPROIC ACID;

ADULTHOOD; AUTISM; BRAIN DEVELOPMENT; BRAIN MAPPING; CENTRAL NERVOUS SYSTEM; COGNITION; DEVELOPMENTAL STAGE; DRUG EXPOSURE; EPIGENETICS; EPILEPSY; EXPERIMENTAL ANIMAL; HUMAN; LIFESPAN; LONG TERM EXPOSURE; MENTAL DISEASE; MYELINATION; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROCONNECTIVITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERINATAL PERIOD; PRIMATE; PRIORITY JOURNAL; REMYELINIZATION; REVIEW;

ANIMALS; BRAIN; EPILEPSY; HUMANS; MODELS, ANIMAL; MYELIN SHEATH; NEUROIMAGING; VALPROIC ACID;

EID: 84864812609     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2012.05.006     Document Type: Review

References (72)

1. Adab N., Kini U., Vinten J., Ayres J., Baker G., et al. The longer term outcome of children born to mothers with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry 2004, 75(11):1575-1583.
2. Arndt T.L., Stodgell C.J., Rodier P.M. The teratology of autism. International Journal of Developmental Neuroscience 2005, 23:189-199.
3. Azorin J.M., Findling R.L. Valproate use in children and adolescents with bipolar disorder. CNS Drugs 2007, 21:1019-1033.
4. Bardai F.H., D'Mello S.R. Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta. Journal of Neuroscience 2011, 31(5):1746-1751.
5. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiology of Aging 2004, 25(1):5-18.
6. Bartzokis G. Brain myelination in prevalent neuropsychiatric developmental disorders: primary and comorbid addiction. Adolescent Psychiatry 2005, 29:55-96.
7. Bartzokis G. Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments. Frontiers in Bioscience 2011, 17:2695L 733.
8. Bartzokis G., Beckson M., Lu P.H., Nuechterlein K.H., et al. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Archives of General Psychiatry 2001, 58(5):461-465.
9. Bartzokis G., Cummings J.L., Sultzer D., Henderson V.W., Nuechterlein K.H., Mintz J. White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Archives of Neurology 2003, 60(3):393-398.
10. Bartzokis G., Sultzer D., Lu P.H., Nuechterlein K.H., Mintz J., Cummings J. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical disconnection in aging and Alzheimer's disease. Neurobiology of Aging 2004, 25(7):843-851.
11. Chuang D.M., Leng Y., Marinova Z., Kim H.J., Chiu C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends in Neurosciences 2009, 32:591-601.
12. D'Ambrosio R., Perucca E. Epilepsy after head injury. Current Opinion in Neurology 2004, 17(6):731-735.
13. Deoni S.C., Mercure E., Blasi A., Gasston D., et al. Mapping infant brain myelination with magnetic resonance imaging. Journal of Neuroscience 2011, 31(2):784-791.
14. Deppe M., Kellinghaus C., Duning T., Möddel G., et al. Nerve fiber impairment of anterior thalamocortical circuitry in juvenile myoclonic epilepsy. Neurology 2008, 71(24):1981-1985.
15. Dietz K.C., Casaccia P. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacological Research 2010, 62(1):11-17.
16. Eyal S., Yagen B., Sobol E., Altschuler Y., Shmuel M., Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004, 45:737-744.
17. Farkas Z., Gulyás S., Molnár R., Szirmai I., Kamondi A. Quantitative analysis of motor performance in epilepsy patients treated with valproate. Seizure 2010, 19(3):173-177.
18. Fischer A., Sananbenesi F., Wang X., Dobbin M., et al. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007, 447(7141):178-182.
19. Fischer A., Sananbenesi F., Mungenast A., Tsai L.H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends in Pharmacological Sciences 2010, 31:605-617.
20. Flechsig P. Developmental (myelogenetic) localisation of the cerebral cortex in the human. Lancet 1901, 158:1027-1030.
21. Fleisher A.S., Truran D., Mai J.T., Langbaum J.B., Aisen P.S., Cummings J.L., Jack C.R., Weiner M.W., Thomas R.G., Schneider L.S., Tariot P.N. Alzheimer's Disease Cooperative Study. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 2011, 77:1263-1271.
22. Gao W., Lin W., Chen Y., Gerig G., Smith J.K., Jewells V., Gilmore J.H. Temporal and spatial development of axonal maturation and myelination of white matter in the developing brain. American Journal of Neuroradiology 2009, 30(2):290-296.
23. Goldberg J.F., Burdick K.E. Cognitive side effects of anticonvulsants. Journal of Clinical Psychiatry 2001, 62:27-33.
24. Gogolla N., Leblanc J.J., Quast K.B., Südhof T.C., Fagiolini M., Hensch T.K. Common circuit defect of excitatory-inhibitory balance in mouse models of autism. Journal of Neurodevelopmental Disorders 2009, 1(2):172-181.
25. Gräff J., Kim D., Dobbin M.M., Tsai L.H. Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiological Reviews 2011, 91:603-649.
26. Guerrini R., Belmonte A., Canapicchi R., Casalini C., Perucca E. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia 1998, 39:27-32.
27. Ha T.H., Her J.Y., Kim J.H., Chang J.S., Cho H.S., Ha K. Similarities and differences of white matter connectivity and water diffusivity in bipolar I and II disorder. Neuroscience Letters 2011, 505:150-154.
28. Hessen E., Lossius M.I., Reinvang I., Gjerstad L. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia 2006, 47(12):2038-2045.
29. Henry T.R. The history of valproate in clinical neuroscience. Psychopharmacology Bulletin 2003, 37:5-16.
30. Huttenlocher P.R., Dabholkar A.S. Regional differences in synaptogenesis in human cerebral cortex. Journal of Comparative Neurology 1997, 387(2):167-178.
31. Jacob C., Lebrun-Julien F., Suter U. How histone deacetylases control myelination. Molecular Neurobiology 2011, 44(3):303-312.
32. Kennedy K.M., Raz N. Aging white matter and cognition: differential effects of regional variations in diffusion properties on memory, executive functions, and speed. Neuropsychologia 2009, 47(3):916-927.
33. Kim D., Frank C.L., Dobbin M.M., Tsunemoto R.K., et al. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron 2008, 60(5):803-817.
34. Kochunov P., Coyle T., Lancaster J., Hardies J., Kochunov V., Bartzokis G., Royall D., Stanley J., Schlosser A., Fox P. Processing speed is correlated with cerebral health markers in the frontal lobes as quantified by neuro-imaging. Neuroimage 2010, 49:1190-1199.
35. Kochunov P., Williamson D.E., Lancaster J., Fox P., Cornell J., Blangero J., Glahn D.C. Fractional anisotropy of water diffusion in cerebral white matter across the lifespan. Neurobiology of Aging 2012, 33:9-20.
36. Konrad A., Vucurevic G., Musso F., Stoeter P., Winterer G. Correlation of brain white matter diffusion anisotropy and mean diffusivity with reaction time in an oddball task. Neuropsychobiology 2009, 60(2):55-66.
37. Lamantia A.S., Rakic P. Cytological and quantitative characteristics of four cerebral commissures in the rhesus monkey. Journal of Comparative Neurology 1990, 291(4):520-537.
38. Larrison A.L., Babin S.L., Xing Y., Patel S.S., et al. Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia. Human Psychopharmacology 2011, 26(7):517-525.
39. LeBlanc J.J., Fagiolini M. Autism: a " critical period" disorder?. Neural Plasticity 2011, 2011:921680.
40. Lehrman G., Hogue I., Palmer S., Jennings C., Spina C., Wiegand A., Landay A., Coombs R., Richman D., Mellors J., Coffin J., Bosch R., Margolis D. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366:549-555.
41. Lossius M.I., Hessen E., Mowinckel P., Stavem K., Erikssen J., Gulbrandsen P., Gjerstad L. Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). Epilepsia 2008, 49(3):455-463.
42. Macritchie K., Geddes J.R., Scott J., Haslam D., de Lima M., Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database of Systematic Reviews 2003, (1):CD004052.
43. Meador K.J., Baker G.A., Browning N., et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. New England Journal of Medicine 2009, 360:1597-1605.
44. Monti B., Polazzi E., Contestabile A. Biochemical molecular and epigenetic mechanisms of VPA neuroprotection. Current Molecular Pharmacology 2009, 2:95-109.
45. Nalivaeva N.N., Belyaev N.D., Turner A.J. Sodium valproate: an old drug with new roles. Trends in Pharmacological Sciences 2009, 30:509-514.
46. Nalivaeva N.N., Belyaev N.D., Lewis D.I., Pickles A.R., Makova N.Z., Bagrova D.I., Dubrovskaya N.M., Plesneva S.A., Zhuravin I.A., Turner A.J. Effect of sodium valproate administration on brain neprilysin expression and memory in rats. Journal of Molecular Neuroscience 2011, 10.1007/s12031-011-9644.
47. O'Muircheartaigh J., Vollmar C., Barker G.J., Kumari V., Symms M.R., Thompson P., Duncan J.S., Koepp M.J., Richardson M.P. Focal structural changes and cognitive dysfunction in juvenile myoclonic epilepsy. Neurology 2011, 76(1):34-40.
48. Peleg S., Sananbenesi F., Zovoilis A., Burkhardt S., Bahari-Javan S., et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010, 328(5979):753-756.
49. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002, 16:695-714.
50. Petanjek Z., JudaŠ M., Šimic G., Rasin M.R., Uylings H.B., Rakic P., Kostovic I. Extraordinary neoteny of synaptic spines in the human prefrontal cortex. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:13281-13286.
51. Price J.L., Drevets W.C. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010, 35:192-216.
52. Pulsipher D.T., Dabbs K., Tuchsherer V., Sheth R.D., Koehn M.A., et al. Thalamofrontal neurodevelopment in new-onset pediatric idiopathic generalized epilepsy. Neurology 2011, 76(1):28-33.
53. Putignano E., Lonetti G., Cancedda L., Ratto G., Costa M., Maffei L., Pizzorusso T. Developmental downregulation of histone posttranslational modifications regulates visual cortical plasticity. Neuron 2007, 53(5):747-759.
54. Rakic P. Genesis of neocortex in human and nonhuman primates. Child and Adolescent Psychiatry: A Comprehensive Textbook 2002, 22-46. Lippincott Williams & Wilkins, Philadelphia. M. Lewis (Ed.).
55. Rinaldi T., Silberberg G., Markram H. Hyperconnectivity of local neocortical microcircuitry induced by prenatal exposure to VPA. Cerebral Cortex 2008, 18:763-770.
56. Ristić A.J., Vojvodić N., Janković S., Sindelić A., Sokić D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia 2006, 47(12):2183-2185.
57. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cellular and Molecular Life Sciences 2007, 64:2090-2103.
58. Salthouse T.A. When does age-related cognitive decline begin?. Neurobiology of Aging 2009, 30(4):507-514.
59. Schwarz C., Volz A., Li C., Leucht S. Valproate for schizophrenia. The Cochrane Library 2010, 5:1-23.
60. Shen S., Li J., Casaccia-Bonnefil P. Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing rat brain. Journal of Cell Biology 2005, 169:577-589.
61. Shen S., Sandoval J., Swiss V.A., Li J., Dupree J., Franklin R.J., Casaccia-Bonnefil P. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nature Neuroscience 2008, 11(9):1024-1034.
62. Shorvon S.D. Longer term outcome of children born to mothers with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry 2004, 75(11):1517-1518.
63. Thomson A.M., Bannister A.P. Interlaminar connections in the neocortex. Cerebral Cortex 2003, 13(1):5-14.
64. Vega W.A., Aguilar-Gaxiola S., Andrade L., Bijl R., Borges G., Caraveo-Anduaga J.J., DeWit D.J., Heeringa S.G., Kessler R.C., Kolody B., Merikangas K.R., Molnar B.E., Walters E.E., Warner L.A., Wittchen H.U. Prevalence and age of onset for drug use in seven international sites: results from the international consortium of psychiatric epidemiology. Drug and Alcohol Dependence 2002, 68:285-297.
65. Vernooij M.W., Ikram M.A., Vrooman H.A., Wielopolski P.A., Krestin G.P., Hofman A., Niessen W.J., Van der Lugt A., Breteler M.M. White matter microstructural integrity and cognitive function in a general elderly population. Archives of General Psychiatry 2009, 66(5):545-553.
66. Vollmar C., O'Muircheartaigh J., Barker G.J., Symms M.R., Thompson P., Kumari V., Duncan J.S., Janz D., Richardson M.P., Koepp M.J. Motor system hyperconnectivity in juvenile myoclonic epilepsy: a cognitive functional magnetic resonance imaging study. Brain 2011, 134(Pt 6):1709-1710.
67. Vostrikov V.M., Uranova N.A., Orlovskaya D.D. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophrenia Research 2007, 94:273-280.
68. Vukadinovic Z., Rosenzweig I. Abnormalities in thalamic neurophysiology in schizophrenia: could psychosis be a result of potassium channel dysfunction?. Neuroscience and Biobehavioral Reviews 2012, 36(2):960-968.
69. Vulliemoz S., Vollmar C., Koepp M.J., Yogarajah M., O'Muircheartaigh J., Carmichael D.W., Stretton J., Richardson M.P., Symms M.R., Duncan J.S. Connectivity of the supplementary motor area in juvenile myoclonic epilepsy and frontal lobe epilepsy. Epilepsia 2011, 52(3):507-514.
70. Washburn J.J., West A.E., Heil J.A. Treatment of pediatric bipolar disorder: a review. Minerva Psichiatrica 2011, 52:21-35.
71. Yu Y., Casaccia P., Lu Q.R. Shaping the oligodendrocyte identity by epigenetic control. Epigenetics 2010, 5:124-128.
72. Zhang B., Wang X., Nazarali A.J. Ascorbic acid reverses valproic acid-induced inhibition of hoxa2 and maintains glutathione homeostasis in mouse embryos in culture. Cellular and Molecular Neurobiology 2010, 30:137-148.